Diagnostics and drugmaking made headlines in equal measure, with a UK small-cap pushing a new cancer test into the market while a Big Pharma legal battle played out across the Atlantic. One story centred on expanding patient access, the other on a dispute over how rival obesity and diabetes drugs are marketed to the public.
EDX Medical rolls out bowel cancer test across UK
EDX Medical Group (LON:EDX) has launched its BC95 bowel cancer testing service across the UK, extending early detection capability to a wider patient population. Chief executive Dr Mike Hudson said the service marked "an important contribution to detecting bowel cancer early", framing the rollout as a step toward catching cases before they progress. Shares in EDX Medical ticked up 2.326% to 11.0p on the news.
Novo Nordisk sues Eli Lilly over ad claims
Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing its rival of running misleading nationwide advertisements that pit Lilly's highest-dose diabetes and obesity drugs against lower doses of Novo Nordisk's medicines. The suit sets up a fresh legal confrontation between the two dominant players in the GLP-1 drug market, where marketing claims around comparative efficacy carry significant commercial weight as both companies compete for share of the fast-growing weight-loss and diabetes treatment segment.
